Xiang‐Yang Ye

机构：Hangzhou Normal University, Chinese Anti-Cancer Association, Chengdu University of Traditional Chinese Medicine · ORCID：0000-0003-3739-0930

发表论文 118 篇 · 总被引 3699 次 · h-index 28

代表论文

• Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer Models (2025 · Advanced Science · 被引 12)
• Tetrandrine regulates NAADP-mediated calcium signaling through a LIMP-2-dependent and sphingosine-mediated mechanism (2025 · Nature Communications · 被引 10)
• A novel PARP-ATR dual inhibitor exhibits anti-triple-negative breast cancer activity by inducing excessive DNA damage in the mitotic phase (2025 · Biochemical Pharmacology · 被引 9)
• Olaparib research update: mechanism, structure and clinical trials (2025 · Medicinal Chemistry Research · 被引 8)
• PARP7i Clinical Candidate RBN‐2397 Exerts Antiviral Activity by Modulating Interferon‐β Associated Innate Immune Response in Macrophages (2024 · Drug Development Research · 被引 8)
• β-Elemene inhibits epithelial-mesenchymal transformation in non-small cell lung cancer by targeting ALDH3B2/RPSA axis (2024 · Biochemical Pharmacology · 被引 7)